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ABSTRACT
In human aortic smooth muscle cells, prostaglandin E2 (PGE2)
stimulates adenylyl cyclase (AC) and attenuates the increase in
intracellular free Ca21 concentration evoked by activation of
histamine H1 receptors. The mechanisms are not resolved. We
show that cAMP mediates inhibition of histamine-evoked Ca21
signals by PGE2. Exchange proteins activated by cAMP were
not required, but the effects were attenuated by inhibition of
cAMP-dependent protein kinase (PKA). PGE2 had no effect on
the Ca21 signals evoked by protease-activated receptors, heter-
ologously expressed muscarinic M3 receptors, or by direct
activation of inositol 1,4,5-trisphosphate (IP3) receptors by pho-
tolysis of caged IP3. The rate of Ca
21 removal from the cytosol
was unaffected by PGE2, but PGE2 attenuated histamine-
evoked IP3 accumulation. Substantial inhibition of AC had no
effect on the concentration-dependent inhibition of Ca21 signals
by PGE2 or butaprost (to activate EP2 receptors selectively), but it
modestly attenuated responses to EP4 receptors, activation of
which generated less cAMP than EP2 receptors. We conclude
that inhibition of histamine-evoked Ca21 signals by PGE2 occurs
through “hyperactive signaling junctions,”wherein cAMP is locally
delivered to PKA at supersaturating concentrations to cause
uncoupling of H1 receptors from phospholipase C. This sequence
allows digital signaling from PGE2 receptors, through cAMP and
PKA, to histamine-evoked Ca21 signals.
Introduction
Ca21 and cAMP are ubiquitous intracellular messengers
that regulate most cellular behaviors. The versatility of these
messengers depends on both the spatiotemporal organization
of the changes in their concentration within cells (Cooper and
Tabbasum, 2014) and on interactions between them [see
references in Tovey et al. (2008)]. These interactions are
important in many smooth muscles, where increases in
intracellular free Ca21 concentration ([Ca21]i) stimulate
contraction, but receptors that stimulate formation of cAMP
usually cause relaxation. The clinical importance is clear from
thewidespread use of b-agonists to provide symptomatic relief
from asthma (Morgan et al., 2014). In vascular smooth muscle
(VSM), too, cAMP attenuates the contractile responses medi-
ated by many receptors that evoke Ca21 signals (Morgado
et al., 2012). This inhibition is assumed to be mediated by
cAMP-dependent protein kinase (PKA) (Murthy, 2006), but
there are also PKA-independent effects of cAMP (Spicuzza
et al., 2001). At least some of these effects may be through
exchange proteins activated by cAMP (EPACs), probably
EPAC 1, which is abundant in blood vessels particularly
within endothelial cells (Roscioni et al., 2011).
Histamine and prostaglandin E2 (PGE2) are two important
inflammatory mediators. Their effects on VSM, which include
regulation of proliferation (Yau and Zahradka, 2003) and
vascular tone (Toda, 1987; Jadhav et al., 2004), are mediated
by direct interactions with VSM and indirectly through
release of autocrine signals from other cells (Norel, 2007).
Histamine, PGE2 and their receptors are also implicated in
vascular pathology, including inflammation (Norel, 2007),
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ABBREVIATIONS: AC, adenylyl cyclase; AKAP, A kinase-anchoring protein; ASMC, aortic smooth muscle cell; [Ca21]i, intracellular free [Ca
21]; ci-IP3,
D-2,3-O-isopropylidene-6-O-(2-nitro-4,5-dimethoxy)benzyl-myo-inositol 1,4,5-trisphosphate; ci-IP3PM, ci-IP3-hexakis(propionoxymethyl) ester; DDA, 29,59-
dideoxyadenosine; EPAC, exchange protein activated by cAMP; ESI-09, 3-[5-(tert-butyl)isoxazol-3-yl]-2-[2-(3-chlorophenyl)hydrazono]-3-oxopropanenitrile;
HBS, HEPES-buffered saline; HJC0197, 4-cyclopentyl-2-(2,5-dimethylbenzylsulfanyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile; H89, N-[2-[[3-(4-bromo-
phenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide dihydrochloride; IBMX, 3-isobutyl-1-methylxanthine; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3
receptor; L902, 688 (5-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl]-1-[6-(2H-tetrazol-5R-yl)hexyl]-2-pyrrolidinone); NKH 477, (N,N-dimethyl-
(3R,4aR,5S,6aS,10S,10aR,10bS)-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho[2,1-b]pyran-
6-yl ester b-alanine hydrochloride); PAR1, protease-activated receptor type 1; PDE, cyclic nucleotide phosphodiesterase; pIC50 (pEC50),
negative logarithm of the half-maximally inhibitory (effective) concentration; PGE2, prostaglandin E2; PKA, cAMP-dependent protein
kinase; PKG, cGMP-dependent protein kinase; PKI (mut PKI), PKA inhibitor peptide (mutant inactive form); PLC, phospholipase C; SQ
22536, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine; SQ/DDA, 1 mM SQ 22536 with 200 mM DDA; TBS, Tris-buffered saline; TBS-T, TBS
with Tween; VASP, vasodilator-stimulated phosphoprotein; VSM, vascular smooth muscle.
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atherosclerosis (Gómez-Hernández et al., 2006), and resteno-
sis (Sasaguri et al., 2005).
We demonstrated previously that histamine, through H1
receptors, stimulates an increase in [Ca21]i in human aortic
smooth muscle cells (ASMC). The initial response is mediated
by Ca21 release through inositol 1,4,5-trisphosphate receptors
(IP3R) and it is followed by Ca
21 entry across the plasma
membrane (Pantazaka et al., 2013). PGE2, acting largely
throughEP2 receptors, both stimulates the activity of adenylyl
cyclase (AC) and substantially attenuates the Ca21 signals
evoked by histamine. Here, we show that inhibition of
histamine-evoked Ca21 signals by PGE2 is mediated by
cAMP delivered within “hyperactive signaling junctions.”
The response does not require EPACs, but it is attenuated by
inhibition of PKA. The effect of PGE2 on histamine-evoked
Ca21 signals does not result from a decrease in IP3R sensitivity
or from increased Ca21 extrusion from the cytosol, nor does
PGE2 affect the Ca
21 signals evoked by stimulation of either
endogenous type 1 protease-activated receptor (PAR1) or
heterologously expressed muscarinic M3 acetylcholine recep-
tors. We suggest that PKA uncouples H1 histamine receptors
from the guanine nucleotide-binding protein, Gq/11, and activa-
tion of phospholipase C (PLC). Our results establish that digital
signaling from PGE2 receptors, through cAMP and PKA,
inhibits histamine-evoked Ca21 signals.
Materials and Methods
Materials. H89, NKH 477, 8-Br-cAMP, and 8-Br-cGMP were from
R&D Systems (Abingdon, Oxford, UK). Sp-cAMPS, 6-Bnz-cAMP,
8-pCPT-29-O-Me-cAMP, Rp-cAMPS, Rp-8-CPT-cAMPS, ESI-09, and
HJC0197 were from Biolog (Bremen, Germany). Ionomycin, SQ
22536, DDA and myristoylated-PKA inhibitor peptide (PKI) were from
Merck-Millipore (Watford, UK). A membrane-permeant peptide
inhibitor of A kinase-anchoring proteins (AKAPs) [stearated Ht31
AKAP inhibitor peptide (st-Ht31)] and its proline-modified inactive
form (st-Ht31P) were from Promega (Southampton, UK). Thapsigargin
was from Alomone Laboratories (Jerusalem, Israel). PAR1 peptide,
histamine dihydrochloride, forskolin, IBMX, and PGE2 were from
Sigma-Aldrich (Welwyn Garden City, UK). Butaprost (free acid) and
L902,688 were from Cayman Chemicals (Ann Arbor, MI). Membrane-
permeant caged IP3 (ci-IP3PM) was from SiChem (Bremen, Germany).
[2,8-3H] adenine ci-IP3PM, D-2,3-O-isopropylidene-6-O-(2-nitro-4,5-
dimethoxy)benzyl-myo-inositol 1,4,5-trisphosphate-hexakis(propionox-
ymethyl) ester was from Perkin Elmer (Seer Green, Bucks, UK). Fluo-8
was from Stratech Scientific Ltd (Newmarket, Suffolk, UK). Other
reagents were from Sigma-Aldrich, sources specified previously
(Pantazaka et al., 2013) or identified in this section.
Culture of Human Aortic Smooth Muscle Cells. Human
ASMC from the American Tissue Culture Collection (Manassas, VA)
orDr. Trevor Littlewood (Boyle et al., 2002) were cultured as described
(Pantazaka et al., 2013). Ethical approval for the latter was obtained
from Addenbrooke’s NHS Trust. Cells were derived from four
Caucasian patients (males aged 23, 52, and 54, and a female aged
58), who died of causes unrelated to cardiovascular pathologies. Cells
were used between passages two and six.
Measurements of [Ca21]i. Histamine-evoked changes in [Ca21]i
were recorded from cell populations using confluent cultures of ASMC
grown in 96-well plates and loadedwith Fluo-4 or Fluo-8. Experiments
were performed in HEPES-buffered saline (HBS) at 20°C. HBS had
the following composition (mM): NaCl 135, KCl 5.9, MgCl2 1.2, CaCl2
1.5, glucose 11.5, andHEPES11.6 (pH7.3). Fluorescencewas recorded
using a FlexStation 3 fluorescence plate-reader (MDS Analytical
Technologies, Wokingham, UK) and calibrated to [Ca21]i as described
(Pantazaka et al., 2013).
For measurements of [Ca21]i in single cells, confluent cultures of
ASMC grown on poly-L-lysine-coated coverslips (22-mm diameter)
were loaded with Fura-2 in HBS containing Fura-2 AM (4 mM),
probenecid (2.5 mM), and pluronic F127 (0.02% v/v) for 1 hour at 20°C.
Fluorescence (detected at .510 nm with alternating excitation at
340 and 380 nm) was recorded using an Olympus IX71 inverted
fluorescence microscope and Luca (electron-multiplying charge-
coupled device) EMCCDAndor Technology, Belfast, UK camera. After
correction for background fluorescence, determined by addition of
ionomycin (1–5 mM) in HBS containing MnCl2 (1 mM), fluorescence
ratios (F340/F380) were calibrated to [Ca
21]i (Tovey et al., 2003).
Measurements of Intracellular cAMP. Confluent cultures of
ASMC grown in 24-well plates and labeled with 3H-adenine were
incubated under conditions that replicated those used for measure-
ments of [Ca21]i. Reactions were terminated by aspiration of medium
and addition of ice-cold trichloroacetic acid (5% v/v, 1 ml). After
30 minutes on ice, 3H-cAMP was separated from other 3H-labeled
adenine nucleotides (Pantazaka et al., 2013).
Expression of PKI and M3 Muscarinic Receptors. Plasmids
encoding PKI (pRSV-PKI-v2) and its inactive form (pRSV-mut PKI-v2)
were fromAddgene (cat. no. 45066 and cat. no. 45067; Cambridge,MA)
(Day et al., 1989); they were C-terminally tagged with mCherry.
Plasmid encoding the human M3 muscarinic acetylcholine receptor
was from the cDNA Resource Centre (cat. no. MAR0300000) (Ford
et al., 2002). The three constructs were each recombined into BacMam
pCMV-DEST. Bacmids were then prepared, and virus was produced
from bacmid-infected Sf9 cells according to the manufacturer’s
instructions (Thermo Fisher Scientific, Runcorn, UK). ASMC were
infected at a multiplicity of infection (MOI) of ∼50 and used after
96 hours.
Flash Photolysis of Caged IP3. Confluent cultures of ASMC
grown on poly-L-lysine-coated imaging dishes (35-mm diameter
with a 7-mm glass insert; MatTek Corporation, Ashland, MA) were
loaded (45minutes, 20°C) with amembrane-permeant form of caged
IP3 (ci-IP3PM, 1 mM) in HBS with probenecid (2.5 mM) and pluronic
F127 (0.02% v/v). Fluo-4 AM (4 mM) was then added and after
45 minutes at 20°C, the medium was replaced with HBS containing
only probenecid. After a further 45 minutes, this medium was
replaced with HBS. Cells were illuminated with a 488-nm diode-
based solid-state laser, and emitted fluorescence (500–550 nm)
was captured with an EMCCD camera. Three UV flashes (each
∼1-millisecond duration; ,345 nm, 3000 mF, 300 V, ∼170 J) from a
JML-C2 Xe flash-lamp (Rapp OptoElectronic, Hamburg, Germany)
allowed photolysis of caged IP3 (ci-IP3). Responses are reported asF/F0,
where F0 and F are fluorescence intensities corrected for background
recorded from the same region of interest immediately before (F0) and
after stimulation (F).
Measurements of IP3 and PLC Activity. ASMC in 12-well
plates were cultured until confluent. The medium was then supple-
mented with D-myo-[2-3H]-inositol (10 mCi/ml) for 48 hours at 37°C.
After washing, cells were incubated at 20°C in HBSwith LiCl (10mM)
for 5 minutes before stimulation. Reactions were terminated by
aspirating medium and adding cold HClO4 (1 ml, 0.6 M) containing
phytic acid (0.2 mg/ml). After 30 minutes, the acid-extract was
removed, the cells were scraped into 50 mM Tris at pH 7 (400 ml),
and the pooled extract and cells were centrifuged (10,000g, 2 minutes,
4°C). The supernatant was neutralized using K2CO3 (1M) with EDTA
(5 mM). 3H-inositol phosphates were separated using ion-exchange
columns.
For assays of IP3 mass, ASMC in 75-cm
2 flasks were stimulated,
the medium was removed, and the incubations were terminated by
scraping cells into ice-cold ethanol (1 ml). After 30 minutes, extracts
were dried and suspended in 300 ml of Tris-EDTA medium (TEM:
50 mMTris, 1 mMEDTA, pH 8.3). Equilibrium-competition binding
using 3H-IP3 (4.5 nM, 19.3 Ci/mmol), rat cerebellar membranes
(10 mg) and cell extract (20–100 ml) in a final volume of 200 ml of
TEM was used to determine the IP3 content of the extracts (Rossi
et al., 2009).
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Immunoblotting. Confluent ASMC in 75-cm2 flasks or six-well
plates were stimulated and then scraped into cold phosphate-buffered
saline supplemented with Triton-X-100 (1% w/v), protease inhibitors
(one mini-tablet per 10 ml; Roche Applied Science, Burgess Hill, UK),
and phosphatase inhibitors (10 ml/ml; Sigma-Aldrich). Scraped cells
were disrupted by ∼30 passages through a 28-gauge needle and
sonicated (3  10 seconds). Proteins were separated by SDS-PAGE
(NuPAGE 4%–12% Bis-Tris gels; Invitrogen, Paisley, UK) and trans-
ferred to a polyvinylidene difluoride membrane (iBlot; Invitrogen).
Membranes were washed (5 minutes) with Tris-buffered saline (TBS:
137 mM NaCl, 20 mM Tris, pH 7.6), blocked by incubation in TBS
containing 0.1% Tween-20 (TBS-T) and 5% (w/v) nonfat milk powder
(1 hour, 20°C), and then washed with TBS-T (3  5 minutes). Blots
were incubated for 12 hours at 4°C with primary antibody (1:1000) in
TBS-T with 5% (w/v) BSA. After washing (3  5 minutes), blots were
incubated with horseradish peroxidase-conjugated donkey anti-rabbit
secondary antibody (1:2000; SantaCruz Biotechnology, Dallas, TX) for
1 hour in TBS-T with 5% (w/v) nonfat milk powder. After further
washing (3  5 minutes), bands were detected using ECL Prime (GE
Healthcare, Chalfont St Giles, UK) and quantified using GeneTools
(Syngene, Cambridge, UK). The primary rabbit antibodies recognize
PKA-phosphorylated sequences RXXS*/T* (AbP1, AbP2, cat. nos.
9621 and 9624; New England Biolabs, Hitchin, UK; * denotes the
phosphorylated residue) and vasodilator-stimulated phosphoprotein
(VASP [clone 43, BD Biosciences, San Jose, CA]) phosphorylated at
Ser-157 (New England Biolabs) or VASP clone 43 (BD Biosciences,
San Jose, CA).
Quantitative PCR Analysis. QPCR was performed as described
(Tovey et al., 2008) using primers specific for AC subtypes (Ludwig
and Seuwen, 2002) and calibrated against expression of the house-
keeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Pantazaka et al., 2013). Human BioBank cDNA pooled from a variety
of tissues (Primerdesign, Southampton, UK) was used as a positive
control for AC subtypes not expressed in ASMC.
Statistical Analysis. Concentration-effect relationships were
individually fitted by nonlinear curve-fitting to Hill equations
(GraphPad Prism, La Jolla, CA). The absolute sensitivities
and amplitudes of the responses to histamine and PGE2 varied
between patients andwith cell passage. Results are, therefore, often
presented as normalized values (e.g., as percentages of a maximal
response) or as differences between paired comparisons (e.g.,
DpIC50). Two-tailed paired or unpaired Student’s t test, or one-
way analysis of variance followed by Bonferroni’s test, were used as
appropriate.
Results
Cyclic AMP Mediates Inhibition of Histamine-
Evoked Ca21 Signals by PGE2. Figure 1A demonstrates
that PGE2 inhibits the Ca
21 signals evoked by histamine in
human ASMC. Most experiments were performed at 20°C to
minimize loss of the cytosolic Ca21 indicator. However, in
parallel analyses we confirmed that a maximally effective
concentration of PGE2 (10 mM) caused indistinguishable
inhibition of the Ca21 signals evoked by histamine (100 mM)
whether the analyses were performed at 20°C (47% 6 12%
inhibition, n 5 4) or 37°C (45% 6 6%). In parallel measure-
ments of the effects of PGE2 on intracellular cAMP and
histamine-evoked Ca21 signals, the cAMP response [negative
logarithm of the half-maximally effective concentration
(pEC50) 5 6.76 6 0.09, n 5 4) was ∼140-fold less sensitive to
PGE2 than were the Ca
21 signals [negative logarithm of the
half-maximally inhibitory concentration (pIC50) 5 8.90 6
0.10, n 5 6] (Fig. 1B). This relationship is consistent with
PGE2 evoking formation of more cAMP than needed to
maximally inhibit Ca21 signals, and with cAMP lying up-
stream of the inhibition of Ca21 signaling (Strickland and
Loeb, 1981).
Forskolin and its water-soluble analog, NKH 477, directly
activate eight of the nine membrane-bound forms of AC
(AC1–8) (Seifert et al., 2012). Pretreatment of ASMC with
NKH 477 caused a concentration-dependent reduction in both
the peak amplitudes of the Ca21 signals evoked by histamine
and their sensitivity to histamine (Fig. 1C; Table 1). Similar
results were obtained with forskolin (Fig. 1D). Maximally
effective concentrations of PGE2 and NKH 477 caused indis-
tinguishable inhibition of histamine-evoked Ca21 signals, and
their combined maximal effects were not additive (Fig. 1E).
These results are consistent with reports showing that
forskolin and NKH 477 attenuate the Ca21 signals evoked
by receptors, including H1 receptors that stimulate PLC in
VSM (Yang et al., 1999, and references therein) and other
smooth muscles. There has, however, been no prior demon-
stration that activation of AC inhibits PLC-evoked Ca21
signals in human ASMC.
High concentrations of 8-Br-cAMP also inhibited histamine-
evoked Ca21 signals by reducing the maximal response and
the sensitivity to histamine (Fig. 2A). 8-Br-cAMP had no effect
on the Ca21 content of the intracellular stores (Fig. 2B). The
effects of 8-Br-cAMP were mimicked by Sp-cAMPS, which
activates PKA and EPACs, and by 6-Bnz-cAMP and 8-CPT-6-
Phe-cAMP, which activate PKA but not EPACs (Fig. 2C;
Supplemental Fig. S1; and Table 1). A high concentration
(10 mM) of 8-pCPT-29-O-Me-cAMP, a membrane-permeant
activator of EPACs; and Rp-cAMPS and Rp-8-CPT-cAMPS,
antagonists of both PKA andEPACs, were ineffective (Fig. 2D;
Supplemental Fig. S1).
The negative result with 8-pCPT-29-O-Me-cAMP is impor-
tant because this analog is more membrane-permeable than
8-Br-cAMP, and it both binds with greater affinity than cAMP
to EPACs and more effectively activates them (Gloerich and
Bos, 2010). Furthermore, antagonists of EPACs 1 and 2,
HJC0197 (Chen et al., 2012), and ESI-09 (Almahariq et al.,
2013) (10 mM, 20 minutes) did not prevent the inhibition of
histamine-evoked Ca21 signals by PGE2 (Fig. 2E). Higher
concentrations (50 mM) of either antagonist abolished the
Ca21 signals evoked by histamine (data not shown). We have
not explored this effect further, although the antagonists
caused similar inhibition of carbachol-evoked Ca21 signals
in human embryonic kidney 293 cells (Meena et al., 2015).
Others have also reported nonspecific effects of these EPAC
antagonists (Rehmann, 2013).
Maximally effective concentrations of PGE2, forskolin, NKH
477, or 8-Br-cAMP similarly attenuated the Ca21 signals
evoked by histamine, and combinations of the treatments
were not additive (Fig. 2D). These results establish that
inhibition of histamine-evoked Ca21 signals by PGE2 is
mediated by cAMP (Fig. 2F) and does not require EPACs.
Inhibition of Histamine-Evoked Ca21 Signals by
PGE2 is Not Mediated by cGMP-Dependent Protein
Kinase. Cyclic AMP may directly activate PKG in arterial
smooth muscle, although this is contentious [see references in
Morgan et al. (2014)]. Cyclic AMP could, however, increase the
concentration of cGMPby competingwith it for degradation by
cyclic nucleotide phosphodiesterases (PDEs). Stimulation of
PKG might then attenuate IP3-evoked Ca
21 release (Masuda
et al., 2010). There is evidence, however, that expression of
Inhibition of Ca21 Signals by cAMP Signaling Junctions 535
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proteins involved in PKG signaling in VSMare downregulated
in culture (Lincoln et al., 2006, and references therein). 8-Br-
cGMP (pIC50 5 4.50 6 0.29, n 5 5) partially inhibited Ca
21
signals evoked by a submaximal concentration of histamine,
but the maximal inhibition was less than half that evoked by
PGE2 or 8-Br-cAMP (Fig. 3, A and B). Furthermore, and in
contrast to the effects of 8-Br-cAMP (Fig. 2C), 8-Br-cGMP did
not inhibit the Ca21 signals evoked by a maximal histamine
concentration (Fig. 2D). Prolonged incubation with IBMX
(20 minutes, 1 mM), a nonselective inhibitor of PDEs,
inhibited histamine-evoked Ca21 signals, but the inhibition
(33%6 3%, n5 4) was less than that caused by PGE2 (56% 6
3%) (Fig. 3C). More importantly, a maximal concentration of
PGE2 similarly inhibited histamine-evoked Ca
21 signals in
Fig. 1. Inhibition of histamine-evoked Ca2+ signals by PGE2 is mediated by cAMP. (A) Ca2+ signals evoked by histamine (3 mM, black bar) alone or with
PGE2 (10 mM, added 5 minutes before and then during stimulation with histamine). Results show means 6 range from two wells on a single plate; they
are typical of results from at least four independent experiments. (B) Effects of PGE2 on cAMP accumulation (measured after 5minutes) and inhibition of
the peak Ca2+ signals evoked by histamine (3 mM). Results, as percentages of maximal inhibition (Ca2+) or stimulation (cAMP), are means6 S.E.M. from
six and four experiments, respectively. This panel includes some data for cAMPmeasurements that were published previously (Pantazaka et al., 2013).
(C) Effect of NKH 477 (100 mM) on the peak Ca2+ signal evoked by histamine. (D) Concentration-dependent effects of forskolin on the peak Ca2+ signals
evoked by histamine (1 mM). (E) Effect of PGE2 (10 mM), NKH 477 (100 mM), or both on the peak Ca
2+ signals evoked by histamine (as percentages of the
maximal response). NKH477, forskolin, or PGE2were added 5minutes before and then during stimulationwith histamine. Results showmeans6S.E.M.
from four (C and D) or three (E) independent plates with one to three wells analyzed from each. Ct denotes control.
TABLE 1
Inhibition of histamine-evoked Ca2+ signals by PGE2 and cAMP
Cells were incubated for the times shown with the indicated drugs before recording
the peak increase in [Ca2+]i evoked by histamine (3 mM; 1 mM for forskolin and NKH
477). Results (means 6 S.E.M. from n independent experiments) show the maximal
inhibition of the histamine-evoked Ca2+ signals and the pIC50 for each drug.
pIC50 Maximal inhibition n
/M %
PGE2 (5 min) 9.01 6 0.05 64 6 4 9
Butaprost (5 min) 7.28 6 0.09 61 6 1 6
L902,688 (5 min) 9.35 6 0.10 76 6 4 5
8-Br-cAMP (20 min) 2.98 6 0.20 85 6 3 3
6-Bnz-cAMP (20 min) 3.73 6 0.14 64 6 5 5
Forskolin (5 min) 6.24 6 0.11 57 6 6 4
NKH 477 (5 min) 5.50 6 0.18 53 6 4 5
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the presence and absence of IBMX (Fig. 3C), demonstrating
that the effects of PGE2 are not mediated by inhibition of
PDEs. We conclude that inhibition of histamine-evoked Ca21
signals by PGE2 is not mediated by inhibition of PDEs and
consequent accumulation of cGMP.
Histamine and 8-Br-cAMP Stimulate PKA-Mediated
Protein Phosphorylation in Different Microenviron-
ments. Most effects of cAMP are mediated by PKA, EPACs,
or cyclic nucleotide-regulated plasma membrane cation chan-
nels (Gloerich and Bos, 2010; Cooper and Tabbasum, 2014).
Fig. 2. Cyclic AMPmediates inhibition of histamine-evokedCa2+ signals byPGE2. (A) Effect of 8-Br-cAMP (added 20minutes before histamine) on the peak
Ca2+ signals evoked by the indicated concentrations of histamine.Results aremeans6S.E.M. fromat least three experimentswith one to threewells in each.
(B) 8-Br-cAMP (10 mM, 20minutes) had no effect on the Ca2+ content of the intracellular stores as revealed by the increases in [Ca2+]i evoked by addition of
thapsigargin (1mM) or ionomycin (1mΜ) inCa2+-freeHBS.Results (percentages of responseswithout 8-Br-cAMP) aremeans6S.E.M. from five experiments
with three to fourwells analyzed in each. (C) Effect of the indicated cyclic nucleotides (added 20minutes before histamine) on the peakCa2+ signals evoked by
histamine (3 mM). Results are means 6 S.E.M. from three to five experiments with two to three wells in each. (D) Effect of NKH 477 (100 mM, 5 minutes),
forskolin (100mM, 5minutes), 8-Br-cAMP (10mM, 20minutes), PGE2 (10mΜ, 5minutes), 8-Br-cGMP (10mM, 20minutes),Rp-cAMPS (10mM, 20minutes),
or 8-pCPT-29-O-Me-cAMP (10mM, 20minutes) alone or in combination on the peak Ca2+ signals evoked by histamine (1mM). Results (as percentages of the
response to histamine alone) aremeans6S.E.M. from three experiments with two to threewells in each. Results forRp-cAMPSare froma single experiment
with three replicates, limited by the availability of this expensive analog. (E) Effects of the EPAC antagonists, ESI-09 and HJC0197 (10 mM, 20minutes), on
the Ca2+ signals evoked by histamine (3 mM) added 5 minutes before and then during treatment with the indicated concentrations of PGE2. Results are
expressed as percentages of the paired response to histamine alone (means6 S.E.M., n = 3–5; n = 2 for the antagonists with 1 and 3 nM PGE2, where error
bars show ranges). (F) The results establish that cAMP mediates inhibition of histamine-evoked Ca2+ signals by PGE2.
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The latter cannot mediate the effects of cAMP on IP3-evoked
Ca21 release, nor are EPACs responsible. We therefore
assessed the role of PKA.
Immunoblotting with an antiserum that recognizes
sequences phosphorylated by PKA showed that maximally
effective concentrations of PGE2 or 8-Br-cAMP stimulated
similar levels of protein phosphorylation in ASMC and their
effects were nonadditive (Fig. 4A). The phosphorylation was
mimicked by 6-Bnz-cAMP but not by the EPAC-selective
analog 8-pCPT-29-O-Me-cAMP (Fig. 4A). PGE2-evoked protein
phosphorylation was attenuated by inhibition of either PKA
(with H89) or AC [with 1 mM SQ 22536 with 200 mM DDA
(SQ/DDA)] (Fig. 4B).
Maximal concentrations of PGE2 and 8-Br-cAMP caused
phosphorylation of the same proteins (Fig. 4A), but the
two stimuli differed in their susceptibility to PKA inhibitors.
Rp-8-CPT-cAMPS, an inhibitor of PKA that competes with
cAMP by binding to the regulatory subunit of PKA, abolished
the phosphorylation evoked by 8-Br-cAMP but only partially
inhibited that evoked by PGE2 (Fig. 4C). Conversely, H89,
which inhibits PKA (and other kinases) by competing for
the ATP-binding site, abolished the phosphorylation evoked
by PGE2 but caused lesser inhibition of the response to
8-Br-cAMP (Fig. 4C). Similar results were obtained when
an antiserum to phospho-VASP was used to assess PKA-
mediated phosphorylation (Supplemental Fig. S2).
These results suggest that PKA activated by PGE2 may be
exposed to high local concentrations of cAMP, which might
then effectively compete with the inhibitor Rp-8-CPT-cAMPS.
Conversely, PKA activated by 8-Br-cAMP, which would
probably be uniformly distributed within the cell, may be
more accessible to ATP than PKA activated by PGE2, and so
less susceptible to inhibition by H89.
Inhibition of Histamine-Evoked Ca21 Signals by
PGE2 Is Attenuated by Inhibition of PKA. Inhibition of
histamine-evoked Ca21 signals by PGE2 or 8-Br-cAMP was
inhibited by Rp-8-CPT-cAMPS (1 mM), which reduced the
sensitivity to PGE2 (decreasing the pIC50 for PGE2 from 8.68 6
0.17 to 8.26 6 0.05, n 5 3; DpIC50 5 0.4 6 0.1, where DpIC50 5
pIC50
control – pIC50
Rp-8-CPT-cAMPS) and 8-Br-cAMP (DpIC50 5
0.6 6 0.1) without affecting the maximal inhibition (Fig. 5, A
and B). These results are consistent with Rp-8-CPT-cAMPS
competitively inhibiting cAMP binding to PKA and thereby
attenuating the effects of cAMP on Ca21 signals.
H89 (10 mM) also attenuated the inhibition of histamine-
evoked Ca21 signals by 8-Br-cAMP (DpIC50 5 1.13 6 0.18
n 5 3) and PGE2 (Fig. 5, A and B). In keeping with our
analyses of protein phosphorylation (Fig. 4C), the inhibition
of histamine-evoked Ca21 signals bymaximal concentrations
of PGE2 were less effectively inhibited by H89 than were the
effects of maximal concentrations of 8-Br-cAMP (compare
Fig. 5, A and B).
PKI inhibits PKA by competing with its peptide substrates.
We could not achieve effective inhibition of PKA-mediated
protein phosphorylation with myristoylated-PKI (10 mM,
20 minutes, data not shown). But using a baculovirus, we
achieved expression of PKI in .90% of cells, and this caused
49% 6 6% (n 5 3) inhibition of the VASP phosphorylation
evoked byPGE2 (100nM) (SupplementalFig. S3). Expression of
an inactive PKI (mut PKI) had no effect on PGE2-evoked
protein phosphorylation (Supplemental Fig. S3). The effects
of H89 and PKI on the inhibition of histamine-evoked
Fig. 3. Inhibition of histamine-evokedCa2+ signals by PGE2 is notmediated by
cGMP. (A) Concentration-dependent effects of 8-Br-cGMP (20 minutes) on the
peakCa2+ signals evokedbyhistamine (3mM). (B)Similar experiments showthe
responses tohistamine (3mM)afterpreincubationwithPGE2 (10mM,5minutes)
and/or the indicated concentrations of 8-Br-cAMP or 8-Br-cGMP (20 minutes).
(C) Peak Ca2+ signals evoked by histamine alone or after incubation with IBMX
(1mM,20minutes),PGE2 (10mM,5minutes), or both.Results (aspercentages of
response to histamine alone) are means 6 S.E.M. from five (A), three to six
(B; n = 2 for 3 and 5 mM 8-Br-cAMP, where ranges are shown), and four to
seven (C) independent experiments with two to three wells in each.
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Ca21 signals by PGE2 were similar: Each substantially
reduced themaximal inhibition without significantly affecting
the IC50 for PGE2 (Fig. 5, A and C). The effects of H89 on
inhibition of histamine-evoked Ca21 signals by selective
agonists of EP2 (butaprost) and EP4 (L902,688) receptors were
similar to those observed with PGE2 (Supplemental Fig. S4).
We conclude that inhibition of histamine-evoked Ca21 signals
by PGE2 is mediated by cAMP and requires PKA (Fig. 5D).
PGE2 Does Not Inhibit Ca21 Release Evoked by
Direct Activation of IP3Rs. The rate at which [Ca21]i
recovered from the peak Ca21 signal evoked by histamine
was unaffected by PGE2 (half-times for recovery were 19 6 1
and 17 6 1 seconds, after histamine alone or with PGE2,
respectively; n 5 11) (Supplemental Fig. S5). This suggests
that the attenuated Ca21 signals do not result from PGE2
stimulating Ca21 extrusion from the cytosol.
We used flash-photolysis of ci-IP3 to activate IP3R directly in
Fluo-4-loaded ASMC. Single-cell analyses of ASMC estab-
lished that most cells (99%6 1%, from 12 fields) responded to
histamine (1 mM) with an increase in [Ca21]i, and that two
successive challenges with histamine evoked indistinguish-
able Ca21 signals (Fig. 6, A and B). PGE2 reduced the peak
amplitude of the Ca21 signal evoked by a second histamine
challenge by 28% 6 4% (n 5 65 cells), without significantly
affecting the number of cells that responded (91% 6 8% and
83% 6 7% for control and PGE2-treated cells, respectively)
(Fig. 6, C and D). These results confirm that under the condi-
tions used for uncaging ci-IP3, PGE2 inhibits histamine-
evoked Ca21 signals.
ASMC loaded with ci-IP3 responded to UV flashes with
rapid increases in Fluo-4 fluorescence (F/F0, seeMaterials and
Methods). The amplitudes of these signals were less than
those evoked by a maximal concentration of histamine (Fig. 6,
E andF), confirming that responses to photolysis of ci-IP3were
not saturated. Although cells responded similarly to succes-
sive histamine challenges (Fig. 6, A and B), the response to a
second photolysis of ci-IP3 was smaller than the first (Fig. 6G),
presumably because each stimulus depleted a fraction of the
ci-IP3. We therefore used two methods to assess the effects of
PGE2 on the Ca
21 signals evoked by photolysis of ci-IP3. Cells
were either stimulated twice with a UV stimulus, and the
amplitude of the second response (with or without PGE2) was
compared with the first response for each cell (R2/R1) (Fig. 6,
G–I), or cells were stimulated once with UV flashes alone or in
the presence of PGE2 (Fig. 6J). Both analyses concur in
demonstrating that PGE2 has no significant effect on the
Ca21 signals evoked by IP3 (Fig. 6, G–J). The results with
ci-IP3 therefore demonstrate that PGE2 does not affect the
Fig. 4. PGE2 and 8-Br-cAMP stimulate PKA-mediated protein phosphorylation. (A) Typical immunoblot using AbP2 (see Materials and Methods)
showing PKA-phosphorylated proteins from cells stimulated with cAMP analogs (10 mM, 20 minutes) or PGE2 (10 mM, 5 minutes). Summary results
(means6 S.D., n = 3–4) show the band intensity across the entire gel as a percentage of that from cells stimulated with PGE2. Mr markers (kilodaltons)
shown alongside gel. (B) Similar analyses using AbP1 show the effects of H89 (10 mM, 10 minutes) or SQ/DDA (1 mM SQ22536 and 200 mM DDA,
20 minutes) on the phosphorylation of a 75-kDa band in response to PGE2 (10 mM. 5 minutes). Summary results (means 6 S.D., n = 3–5) show
band intensities as percentages of the matched response to PGE2 alone. (C) Similar analysis to (A), for cells stimulated with PGE2 (10 mM, 5 minutes) or
8-Br-cAMP (10mM, 20minutes) alone or after incubation (20minutes) withRp-8-CPT-cAMPS (1mM)H89 (10mM). Results (means6 S.D., n = 3–4) show
the increase in phosphorylation evoked by the indicated stimuli expressed as a percentage of the matched response to PGE2 alone.
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interactions of IP3 with IP3R. Furthermore, because the peak
IP3-evoked Ca
21 signals were unaffected by PGE2 under
conditions where it attenuates responses to histamine (Fig.
6, I and J), the results provide additional evidence that PGE2
does not stimulate Ca21 removal from the cytosol.
The product of ci-IP3 photolysis is an active but modified
form of IP3 (D-2,3-O-isopropylidene-myo-inositol 1,4,5-tri-
sphosphate) (Dakin and Li, 2007) that is not a substrate for
IP3 3-kinase and may differ from IP3 in its rate of dephos-
phorylation. Our results do not therefore exclude the possibil-
ity that PGE2may accelerate degradation of IP3. These results
suggest that PGE2 attenuates histamine-evoked Ca
21 signals
by inhibiting IP3 formation, stimulating IP3 degradation,
and/or disrupting IP3 delivery to IP3Rs.
PGE2 Attenuates Histamine-Evoked Accumulation
of IP3. Using an assay that reports PLC activity (stimula-
tion after blocking inositol monophosphate degradation by
Li1), histamine (1 mM, 30 minutes) stimulated a small
accumulation of 3H-inositol phosphates in ASMC. Although
the response was modestly attenuated by PGE2 (10 mM), the
effect was not statistically significant (Fig. 7A). Using an
IP3R-based bioassay that detects only (1,4,5)IP3, histamine
stimulated IP3 accumulation, and the response was attenu-
ated by PGE2, although the latter again failed to achieve
statistical significance (Fig. 7B). We also attempted to mea-
sure histamine-evoked IP3 formation in single cells using a
fluorescence resonance energy transfer (FRET)-based IP3
sensor (Gulyas et al., 2015), but the signals were too small to
resolve reliably any inhibitory effect of PGE2. Available
genetically encoded IP3 sensors are known to have limited
dynamic range and limited capacity to resolve small changes
in intracellular IP3 concentration (Miyamoto andMikoshiba,
2017).
We assessed the responses of ASMC to other stimuli (ATP,
bradykinin, carbachol, phenylephrine, and thrombin) that
might be expected to evoked Ca21 signals through receptors
that stimulate Gq (results not shown). Only thrombin
reproducibly evoked substantial increases in [Ca21]i. Thrombin
is a protease that cleaves the type 1 protease-activated
receptor (PAR1) to unmask an N-terminal ligand. Thrombin
and the PAR1 peptide itself evoked concentration-dependent
increases in [Ca21]i in ASMC (Fig. 7C). In parallel analyses,
PGE2 (10 mM, 5 minutes) attenuated the Ca
21 signals evoked
by histamine without affecting those evoked by PAR1 peptide
(Fig. 7D). Although the maximal increase in [Ca21]i evoked by
PAR1 peptide was larger than that evoked by histamine, with
concentrations of histamine and the PAR1peptide that evoked
comparable increases in [Ca21]i, only the response to hista-
mine was inhibited by PGE2 (Fig. 7E). After heterologous
expression of humanmuscarinicM3 acetylcholine receptors in
ASMC, carbachol evoked a concentration-dependent (pEC505
7.72 6 0.04, n 5 3) increase in [Ca21]i, with a maximal
increase (272 6 31 nM, n 5 3) comparable to that evoked by
histamine (204 6 13 nM, Fig. 2A). However, the responses to
carbachol were unaffected by PGE2 (Fig. 7F). These results,
demonstrating that PGE2 selectively inhibits the Ca
21 signals
evoked by histamine, suggest that the inhibition probably
does not arise downstream of PLC.
Fig. 5. Inhibition of histamine-evoked Ca2+ signals by PGE2 or 8-Br-cAMP requires PKA. (A and B) Effects of PGE2 (5 minutes) or 8-Br-cAMP
(20 minutes) on the peak Ca2+ signals evoked by histamine (3 mM) alone or with H89 (10 mM, 20 minutes) or Rp-8-CPT-cAMPS (1 mM, 20 minutes). (C)
Effects of PGE2 (5 minutes) on the Ca
2+ signals evoked by histamine (3 mM) in cells infected with baculovirus expressing PKI or its inactive form (mut
PKI). Results (A–C) aremeans6 S.E.M. from three experiments with two to three wells in each. (D) The results suggest that PKAmediates the inhibition
of histamine-evoked Ca2+ signals by PGE2.
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Fig. 6. PGE2 does not inhibit Ca
2+ signals evoked by direct activation of IP3 receptors. (A–D) Typical fluorescence traces from single Fura-2-loaded
ASMC sequentially stimulated with histamine (1 mM) alone (A) or with PGE2 (10 mM) (C). Summary results (means 6 S.E.M., 65 cells from six
independent fields) show peak amplitudes of the first and second responses to histamine in the absence (B) or presence (D) of PGE2. (E) Typical
fluorescence traces from single Fluo-4-loaded ASMC stimulated with a UV flash to photolyse ci-IP3 (red trace) or histamine (1 mM, black trace). (F)
Summary results (means6S.E.M. from 35 and 118 cells, for histamine and ci-IP3 respectively) show peak responses. (G andH) Three typical fluorescence
traces from single ASMC stimulated twice with UV flashes (arrowheads) alone (G) or with PGE2 (10 mM) (H). (I) Summary results (means6 S.E.M. from
50–68 cells) show relative amplitudes of the peak responses (R2/R1). (J) Summary results (means6S.E.M. from 36–43 cells) showF/F0 (seeMaterials and
Methods) for cells stimulated with a UV flash alone or with PGE2 (10 mM added 5 minutes before flash). *P, 0.05, relative to the response to histamine
alone (D, paired Student’s t test) or to the UV flash alone (F, unpaired Student’s t test).
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Histamine-Evoked Ca21 Signals Are Inhibited by
Local cAMP Signals. Inhibitors of AC (SQ/DDA) attenu-
ated PGE2-evoked cAMP formation (by 79% 6 2%, n 5 4)
(Fig. 8A) and protein phosphorylation (Fig. 4B). However,
SQ/DDA had no effect on the inhibition of histamine-evoked
Ca21 signals evoked by PGE2 or butaprost (Fig. 8, B and C).
Although cAMP mediates the inhibition of Ca21 signals by
PGE2, the response to amaximal concentration of PGE2might
survive substantial inhibition of AC because it stimulates
formation of more cAMP than needed to maximally inhibit
Ca21 signals (Fig. 1B). However, the same argument cannot
account for the lack of effect of SQ/DDA on responses to
submaximal concentrations of PGE2. How might a submaxi-
mal response to PGE2 be unaffected by substantial inhibition
of cAMP formation and PKA activity (Fig. 4B; Fig. 8, A and B)?
A possible explanation is that SQ 22356 and DDA, related
inhibitors that bind to the ATP-binding site of AC (Brand
et al., 2013), selectively inhibit subtypes of AC distinct from
those thatmediate the effects of PGE2. Available antibodies do
not allow quantitative assessment of the expression of AC
Fig. 7. PGE2 selectively attenuates activation of PLC by histamine. (A) Accumulation of
3H-inositol phosphates (30minutes) in cells incubated with LiCl
and stimulated with histamine (1 mM) alone or with PGE2 (10 mM). Results are shown as percentages of matched analyses from unstimulated cells. (B)
Mass assays of (1,4,5)IP3 from cells treated with histamine (1 minute) alone or after treatment with PGE2 (10 mM, 5 minutes). Results (A and B) are
means6 S.E.M., n = 3–5, *P, 0.05, relative to 1 mMhistamine, one-way analysis of variance with Bonferroni’s test. (C) Peak Ca2+ signals evoked by the
indicated concentrations of thrombin or PAR1 peptide. (D) Effects of PGE2 (10 mM, 5 minutes) on the peak Ca
2+ signals evoked by the indicated
concentrations of histamine or PAR1 peptide. Results (C and D) are means 6 S.E.M., n = 4–5. (E) Comparison of the effects of PGE2 on Ca
2+ signals of
similar amplitude evoked by histamine or PAR1 peptide. (F) Peak increases in [Ca2+]i in ASMC heterologously expressing M3 muscarinic receptors and
stimulated in Ca2+-free HBS with the indicated concentrations of carbachol alone or with PGE2 (10 mM, 5 minutes). Results are means 6 S.E.M., n = 3,
with six replicates for each. There was no response to carbachol in normal ASMC (data not shown).
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subtypes, but QPCR analysis shows that human ASMC
express similar amounts (∼30%) of AC3, AC7, AC9, some
AC6 (∼10%), and detectable AC4 (∼2%) (Supplemental
Fig. S6). AC9 probably does not mediate the effects of PGE2
on Ca21 signals because AC9 is insensitive to forskolin and
NKH477 (Seifert et al., 2012), whichmimic the effects of PGE2
on Ca21 signals (Fig. 1, C–E; Fig. 2D). Among the remaining
ACs expressed in ASMC, SQ22536 and DDA probably have
some selectivity for AC6 over AC3 and AC7 despite some
inconsistent reports (Pierre et al., 2009; Seifert et al., 2012).
From analyses of individual AC isoforms, maximally effective
concentrations of SQ 22356 (and other P-site inhibitors)
inhibit catalytic activity by only ∼80% [Brand et al. (2013),
but see Onda et al. (2001)]. This is similar to the ∼80%
inhibition of PGE2-evoked cAMP accumulation by SQ/DDA in
ASMC (Fig. 8A), suggesting that the incomplete inhibition
observed in ASMC probably does not reflect the unperturbed
activity of SQ/DDA-insensitive ACs. Furthermore, the effects
Fig. 8. Signaling from EP receptors to Ca2+ signals via cAMP junctions. (A) Concentration-dependent effects of PGE2 on intracellular cAMP (5 minutes)
alone or after treatmentwith SQ/DDA (20minutes). Results [cAMP/(ATP+ADP+ cAMP),%] aremeans6S.E.M. from four experiments [three of thesewere
published inPantazaka et al. (2013)]. (B–D)Concentration-dependent effects of PGE2, butaprost, orL902,688 on theCa
2+ signals evokedbyhistamine (3mM)
in the presence of SQ/DDA (20 minutes). Results are means 6 S.E.M. from nine (B), six (C), or five (D) experiments with two to three wells in each. (E)
Summary data show the effects of SQ/DDA on the inhibition of histamine-evoked Ca2+ signals by concentrations of PGE2 (1 nM), butaprost (30 nM), and
L902,688 (0.3 nM) that approximately match their IC50 values. (F) Junctional delivery of cAMP to the PKA (squares) through which it inhibits (red)
histamine-evoked Ca2+ signals. Activation of EP2 or EP4 receptors with butaprost or L902,688, respectively, inhibits histamine-evoked Ca
2+ signals, but the
latter evokes formation of less cAMP. We propose, from our results with SQ/DDA, that cAMP is locally delivered to PKA within each signaling junction at a
concentrationmore than sufficient to cause amaximal effect. The concentration-dependent inhibition ofCa2+ signals byprostanoids is proposed to result from
recruitment of all-or-nothing cAMP signaling junctions, rather than fromgraded increases in activitywithin individual junctions. EP2 receptors delivermore
cAMP than EP4 receptors and are therefore more resistant to inhibition of AC by SQ/DDA. Hence inhibition of Ca
2+ signals by EP4 receptors is partially
inhibited by SQ/DDA, whereas the response to EP2 receptors is insensitive (right). *P , 0.05, paired Student’s t-test relative to control.
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of PGE2 on protein phosphorylation in ASMC are inhibited by
SQ/DDA (Fig. 4B), again suggesting that the ACs activated by
PGE2 are inhibited. We conclude that the lack of effect of
SQ/DDA on PGE2-mediated inhibition of histamine-evoked
Ca21 signals is probably not the result of ineffective inhibition
of an SQ/DDA-resistant subtype of AC.
To account for the results with SQ/DDA, we suggest that
cAMP is delivered locally to PKA at concentrations more than
sufficient to fully inhibit Ca21 signals. The concentration-
dependent effects of PGE2 might then result from recruitment
of these “hyperactive” cAMP signaling junctions, rather than
from increased activity within individual junctions (Fig. 8F).
This interpretation is consistent with analyses of the effects
of SQ/DDA on the inhibition of Ca21 signals by selective
activation of EP4 receptors. Although activation of EP2 and
EP4 receptors causes similar maximal inhibition of histamine-
evoked Ca21 signals, EP4 receptors cause less stimulation of
AC (Pantazaka et al., 2013). This suggests that EP4 receptors
may less effectively saturate the cAMP signaling junctions.
Whereas inhibition of AC with SQ/DDA had no effect on
the inhibition of histamine-evoked Ca21 signals by PGE2
or butaprost (to selectively activate EP2 receptors), the
sensitivity to L902,688, a selective agonist of EP4 receptors,
was modestly reduced by SQ/DDA (DpIC505 0.326 0.10, n5
5) (Fig. 8, B–E). This observation supports our suggestion that
the subtype(s) of AC that link prostanoid receptors to in-
hibition of Ca21 signals are sensitive to SQ/DDA. Further-
more, these results are consistent with the scheme shown in
Fig. 8F, where we suggest that cAMP is locally delivered
within “hyperactive” signaling junctions at concentrations
more than sufficient to maximally activate the PKA that
inhibits Ca21 signals.
We considered whether AKAPs, which are widely impli-
cated in assembling PKA with its regulators and effectors
(Smith et al., 2017), might contribute to organization of the
cAMP signaling through PKA that leads to inhibition of
histamine-evoked Ca21 signals. A membrane-permeant pep-
tide that disrupts association of AKAPs with PKA (st-Ht31)
but not its inactive analog (st-Ht31P), significantly attenuated
the protein phosphorylation evoked by PGE2, but neither
peptide affected the concentration-dependent inhibition of
histamine-evoked Ca21 signals by PGE2 (Supplemental Fig.
S7). These results suggest that AKAPs are probably not
important components of the signaling pathway from PGE2
to inhibition of Ca21 signals.
Discussion
In human ASMC, the IP3-mediated Ca
21 signals evoked by
activation of H1 histamine receptors are attenuated by PGE2.
Several lines of evidence show that this inhibition is mediated
by cAMP. The concentration-effect relationships for regula-
tion of AC andCa21 signals by PGE2 are consistent with cAMP
lying upstream of Ca21 in the signaling pathway (Fig. 1B),
direct activation of AC or membrane-permeant analogs of
cAMP mimic PGE2, and maximal concentrations of these
drugs are not additive (Figs. 1 and 2). Our conclusion that
cAMP mediates the inhibition of Ca21 signals in human
ASMC is consistent with evidence that many receptors, via
stimulation of AC, attenuate Ca21 signaling in smoothmuscle,
including VSM (Morgado et al., 2012). Inhibition of histamine-
evoked Ca21 signals by PGE2 does not require activation of
EPACs (Fig. 2, D and E). The inhibition is not mediated by
accumulation of cGMP after inhibition of PDEs since neither
cGMP nor inhibition of PDEs effectively mimicked PGE2 (Fig.
3). Inhibition of histamine-evoked Ca21 signals by PGE2 or
8-Br-cAMP was attenuated by inhibition of PKA using H89,
PKI, orRp-8-CPT-cAMPS (Fig. 4).We conclude that inhibition
of histamine-evoked Ca21 signals by PGE2 is (at least largely)
mediated by PKA (Fig. 5D).
PKA can enhance Ca21 removal from the cytosol by
stimulating Ca21 pumps (Tada and Toyofuku, 1998) or the
Na1/Ca21 exchanger (Karashima et al., 2007). However,
accelerated removal of cytosolic Ca21 does not mediate in-
hibition of histamine-evoked Ca21 signals by PGE2 in human
ASMC (Supplemental Fig. S5). Nor would this mechanism be
consistent with the lack of effect of PGE2 on the Ca
21 signals
evoked by stimulation of endogenous PAR1 or heterologously
expressed M3 muscarinic receptors (Fig. 7, D–F). Cyclic AMP
has been proposed to inhibit IP3-evoked Ca
21 release (Bai and
Sanderson, 2006), but PKA (IP3R1 and IP3R2) and cAMP
(IP3R1-3) more often potentiate responses to IP3 (Taylor,
2017). However, under conditions where PGE2 inhibited
histamine-evoked Ca21 signals, it had no effect on the sensi-
tivity of IP3Rs to IP3 (Fig. 6). Steps linking receptors to PLC
can also be inhibited by cAMP (see references in Yang et al.
(1999)). Although two different assays suggested that PGE2
attenuated histamine-evoked PLC activity in human ASMC,
neither analysis demonstrated a statistically significant effect
(Fig. 7, A and B). However, the lack of effect of PGE2 on the
Ca21 signals evoked by PAR1 and muscarinic M3 receptors
(Fig. 7, D–F) suggests that the inhibition of histamine-evoked
Ca21 signals by cAMP/PKA is probably the result of uncou-
pling of H1 histamine receptors from Gq/11. PKA has been
reported to phosphorylate H1 histamine receptors (Kawakami
et al., 2003; Horio et al., 2004), but the functional conse-
quences have not been thoroughly examined (Miyoshi et al.,
2006). We conclude that in human ASMC, PGE2, through EP2
and EP4 receptors (Pantazaka et al., 2013), stimulates AC,
leading to formation of cAMP and uncoupling of histamine
from stimulation of PLC, most probably by PKA-mediated
phosphorylation of H1 receptors.
Cyclic AMP can be locally delivered to intracellular targets
(Zaccolo, 2011; Cooper and Tabbasum, 2014). AKAPs play
prominent roles in targeting cAMP through PKA to specific
cellular responses (Smith et al., 2017), but our results
suggest that AKAPs probably do not contribute to inhibition
of histamine-evoked Ca21 signals by PGE2 (Supplemental
Fig. S7). Our results do, however, reveal an additional
complexity in the pathways linking PGE2 to inhibition of
histamine-evoked Ca21 signals. Although cAMP mediates
this inhibition, the concentration-dependent effects of PGE2
were insensitive to substantial inhibition of AC (Fig. 8).
These results and analyses of the effects of selective activa-
tion of EP2 and EP4 receptors lead to the scheme shown in
Fig. 8F. We suggest that communication between EP recep-
tors and the PKA that inhibits histamine-evoked IP3 forma-
tion is mediated by delivery of cAMP within signaling
junctions. Activation of a junction allows local delivery of a
supersaturating concentration of cAMP to PKA, allowing
each junction to function as a robust on-off switch. We
suggest that the concentration-dependent effects of PGE2
arise from recruitment of these junctions and not from
graded activity within individual junctions. Such digital
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signaling from receptors to intracellular targets via hyper-
active junctions (Fig. 8F) allows robust and reliable com-
munication, and may be a general feature of signaling by
diffusible intracellular messengers (Tovey et al., 2008).
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